An image featuring the FDA approval logo with text announcing the approval of Lumakras (Sotorasib) combined with Vectibix (Panitumumab) for treating colorectal cancer patients with KRAS G12C mutations. A healthcare professional in surgical attire holds a syringe, symbolizing the administration of the new treatment.

FDA Approves Sotorasib / Lumakras + Panitumumab / Vectibix for KRAS G12C Mutation Extending Survival

On January 16, 2025, a significant advancement in cancer treatment was announced. The FDA approved a new therapeutic option for patients battling KRAS G12C-mutated metastatic colorectal cancer. This groundbreaking treatment involves the combination of sotorasib (marketed as Lumakras) with panitumumab (known as Vectibix). This approval comes as a beacon of hope for patients previously treated … Continue reading FDA Approves Sotorasib / Lumakras + Panitumumab / Vectibix for KRAS G12C Mutation Extending Survival

OncologyTube